Clazakizumab: Difference between revisions
Content deleted Content added
→Further reading: not WP:MEDRS |
Replaced citation with a neutral, non-promo, third party reference |
||
| Line 35: | Line 35: | ||
}} |
}} |
||
'''Clazakizumab''' (formerly ALD518 and BMS-945429), an [[investigational drug]], is a [[aglycosylated]], humanized [[monoclonal antibody]] against [[interleukin-6]].<ref name="Handbook">{{cite book|editor1-link=Stefan Dübel, Janice M. Reichert (eds)|title=Handbook of Therapeutic Antibodies, Volume 2|date=2007|publisher=Wiley Blackwell|page=987|url=https://books.google.com/books?id=svHsBQAAQBAJ&pg=PA987&lpg=PA987&dq=Clazakizumab,+BMS-945429+ALD518&source=bl&ots=OSkfdXWflh&sig=SDM6MUhRVekTcRVaQ6SgemQgXAw&hl=en&sa=X&ved=0ahUKEwjW6a-ipdnRAhUpxlQKHUHrCMwQ6AEIPTAG#v=onepage&q=Clazakizumab%2C%20BMS-945429%20ALD518&f=false|accessdate=January 23, 2017}}</ref> Clazakizumab was developed by [[Bristol Myers Squib]] an [[Alder Biopharmaceuticals]]. |
|||
'''Clazakizumab''' (formerly ALD518 and BMS-945429),<ref name=Claz-2B>[http://news.bms.com/press-release/financial-news/promising-phase-iib-data-clazakizumab-patients-moderate-severe-rheumato Promising Phase IIb Data On Clazakizumab In Patients With Moderate-To-Severe Rheumatoid Arthritis To Be Presented At The 2013 Annual Meeting Of The American College Of Rheumatology ]</ref> and [[investigational drug]], is a [[aglycosylated]], humanized [[monoclonal antibody]] against [[interleukin-6]]. Clazakizumab was developed by [[Alder Biopharmaceuticals]] and licensed to Vitaeris, Inc.<ref>https://globenewswire.com/news-release/2016/07/26/859067/0/en/Alder-BioPharmaceuticals-Reports-Second-Quarter-2016-Financial-and-Operating-Results.html</ref> |
|||
==See also== |
==See also== |
||
Revision as of 22:39, 23 January 2017
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL6 |
| Clinical data | |
| Routes of administration | infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C6426H9972N1724O2032S42 |
| Molar mass | 145.2 kg/mol g·mol−1 |
Clazakizumab (formerly ALD518 and BMS-945429), an investigational drug, is a aglycosylated, humanized monoclonal antibody against interleukin-6.[1] Clazakizumab was developed by Bristol Myers Squib an Alder Biopharmaceuticals.
See also
- Tocilizumab (Actemra) an anti-IL-6 receptor mAb
- Anti-IL-6, other anti-interleukin-6 agents
References
- ^ Handbook of Therapeutic Antibodies, Volume 2. Wiley Blackwell. 2007. p. 987. Retrieved January 23, 2017.